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INTRODUCTION
Stem cells (SCs) are defined as cells that show self-
renewal either with or without differentiation, depending
on the symmetry of the division (Donovan and Gearhart,
2006). The different types of SCs and their environ-
ments, the niches, determine the differentiation
pathways they can follow (Mezey et al., 2000). Multi-
potent SCs, such as mesenchymal SCs (MSCs) and he-
matopoietic SCs (HSCs), can only differentiate into a li-
mited number of tissues in the adult individual (Roelandt
et al., 2010). To date, there have been reports of diffe-
rentiation of equine MSCs into cartilage (Hegewald et
al., 2004), bone (Vidal et al., 2006), fat (Koch et al.,
2007), muscle (Martinello et al., 2009) and tendon
(Smith, 2008). Hematopoietic SCs have the ability to
form all the different types of blood cells (Akashi et al.,
2000). Pluripotent SCs, on the other hand, are able to
differentiate into every cell type from the three germ
layers of the embryo (endoderm, mesoderm, and ecto-
derm). Embryonic SCs (ESCs)  are a typical example of
such pluripotent SCs, and to date, six lines of ESCs
have been described in the horse, although their pluri-
potency remains to be demonstrated in vivo (Donovan
and Gearhart, 2006; Paris and Stout, 2010). 
The use of SC therapy in horses is a hot topic (Van
Haver et al., 2008). Mesenchymal SCs (MSCs) obtai-
ned from the bone marrow have frequently been des-
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ABSTRACT 
Equine peripheral blood (ePB) can be used as a source of stem cells (SCs) in horses, both for research and
for practical purposes. A relatively low volume of ePB is sufficient for the purification and expansion of the
SCs. The identification of the SCs is performed by demonstrating the presence (CD34, CD90, CD105 and
CD117) or absence (CD14) of specific markers on the cell surface by means of fluorescent staining, followed
by Fluorescence Activated Cell Sorting (FACS) for sorting out the desired population of SCs. The entire process
of SC isolation and enrichment from ePB typically takes three days, after which the enriched SC sample can
be sent back to the patient for clinical application. The two most common clinical applications of SCs from ePB
will be demonstrated with two field cases. The first case presents a lesion of the body of the suspensory ligament
in a 13-year-old warmblood mare and the second case describes a bacterial ulcerative keratitis in a 20-year-
old warmblood gelding.
SAMENVATTING
Zowel in het kader van de wetenschap als voor praktische doeleinden kan perifeer bloed van het paard als bron
voor stamcellen (SCs) gebruikt worden. Een relatief laag volume perifeer bloed is voldoende om SCs op te zuiveren
en aan te rijken. De identificatie van SCs kan uitgevoerd worden door de aanwezigheid (CD34, CD90, CD105 en
CD117) of afwezigheid (CD14) van specifieke merkers op het celoppervlak die aangetoond worden aan de hand
van een immunofluorescentiekleuring, gevolgd door fluorescence activated cell sorting (FACS) om de gewenste
celpopulatie te sorteren. Het volledige proces van SC-isolatie en aanrijking duurt gemiddeld drie dagen. Daarna kan
het aangerijkte SC-mengsel teruggezonden worden naar de patiënt. Twee interessante toepassingen van SCs uit het
perifeer bloed worden geïllustreerd. Het eerste geval handelt over een laesie in het middelste aspect van de musculus
interosseus medius bij een dertienjarige warmbloedmerrie. Het tweede geval gaat over bacteriële ulceratieve keratitis
bij een twintigjarige warmbloedruin.
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cribed as a novel treatment for tendinopathies (Crovace
et al., 2007; Smith et al., 2003; Smith, 2006; Smith,
2008; Violini et al., 2009). In addition, the admini-
stration of MSCs has been proposed as a promising
treatment for other diseases such as arthrosis (Wilke et
al., 2007), bone fractures (Vidal et al., 2006), hepatic
disorders (Petersen et al., 1999), pancreatic dysfunction
(Santana et al., 2006), myocardial pathologies (Chen et
al., 2006), epithelial defects in the respiratory system
(Nowak and Fucks, 2009) and even neoplastic proces-
ses (Gratwohl et al., 2007).
Besides bone marrow, other possible sources of
MSCs have been described, including fat, liver, umbi-
lical cord (Wharton’s jelly), fetal pancreas and equine
peripheral blood (ePB) (Campagnoli et al., 2001; Eri-
ces et al., 2000; Hu et al., 2003; Kuwana et al., 2003;
Zuk et al., 2001; Zuk et al., 2002; Zvaifler et al.,
2000). Equine peripheral blood represents an interes-
ting source of SCs because of the low invasivity, ease
of harvesting, and low pain levels involved in the har-
vesting procedure. In this report, two clinical cases are
presented where SCs from the ePB were used to treat
a suspensory ligament desmitis (case one) and a bac-
terial ulcerative keratitis (case two). The salient fin-
dings were that these two clinical cases, each with a
long-lasting pathology which did not respond to con-
ventional treatment, showed a significant improve-
ment after treatment with autologous SCs.
LABORATORY TECHNIQUES
A venous blood sample (5-7 ml in EDTA antico -
agulants) was taken from the patient and transported to
the laboratory at a maximum temperature of 7°C. Upon
arrival at the laboratory, the white blood cell fraction
was immediately isolated using a Ficoll-Paque gra-
dient, following the manufacturer’s instructions (Phar-
macia Biotech AB, Uppsala, Sweden), and washed
with phosphate-buffered saline (PBS) to remove un-
wanted red blood cells. The white blood cell fraction
was incubated for 72 hours in a sterile incubator at
37.5°C and 5% CO2 with granulocyte- and monocyte-
colony stimulating factor (G-CSF & M-CSF, Sigma,
Missouri, USA) and interleukine (IL) 1, 3 and 6 (patent
number ThankStem: 07 820 134.0-1222). Since SCs
are fast dividing cells, there was a sufficient number of
SCs after 72 hours in comparison to the number of dif-
ferentiated monocytes. 
Subsequently, the cells were divided in two groups
and incubated simultaneously with saturating amounts
of the fluorescently labeled human antibodies
CD90/CD117 and CD14/CD34/CD105, respectively,
for 30 minutes at room temperature (RT). The antibo-
dies used were CD34-PerCp, CD90-PE, CD105-FITC,
CD117-APC (all from BD Biosciences, San Jose,
USA), and CD14-PE (Biolegend, San Diego, USA).
This mixture was then sorted with a fluorescent acti-
vated cell sorter (FACSAria II cell sorter, BD Biosci-
ences, San Jose, USA) to isolate SCs from the ePB. The
markers used to characterize the equine SCs have all
been previously described to cross react with equine
antigens. Their presence or absence in the isolated
stem cell population is indicated in Table 1. Indeed,
SCs from the ePB isolated and used for the case studies
were clearly positive for the MSC markers CD90 (Mar-
tinello et al., 2009) and CD105 (Hoynowski et al.,
2007), and for the HSC markers CD34 (Martinello et
al., 2009) and CD117 (Martinello et al., 2009), and
they were negative for CD14, a marker used for diffe-
rentiated hematopoietic cells (Guest et al., 2008; Ibra-
him et al., 2007). In addition, the sorting of these cells
resulted in the elimination of the unwanted differenti-
ated cells, and thus a rather pure isolation of a SC po-
pulation with hematopoietic and mesenchymal pro-
perties was obtained.
After sorting, the cells were washed with PBS and
resuspended in a PBS solution, supplemented with
5µM gentamycin. Two sterile 15ml tubes, each with a
5ml suspension of 125 x103 SCs (or 25 x103 SCs/ml)
and 500 x103 SCs (or 100 x103 SCs/ml), were prepared
for intravenous and local application, respectively. The
cells were then transported back to the patient as soon
as possible at 7°C in a cooling box.
FIELD STUDIES
Case report 1: a suspensory ligament desmitis trea-
ted with ePB-derived SCs
History
A 13-year-old Belgian warmblood mare was pre-
sented with lameness and a swelling on the right front
leg. After a thorough examination, the swelling was si-
tuated in the mid-region of the palmarolateral aspect of
the canon bone. The mare was lame in the right front
leg on a straight line, and in the outside leg on the left
circle on a soft surface. On ultrasound examination, he-
terogenic regions were noted in the mid-region of the
suspensory ligament (musculus interosseus medius,
MIM) of the right front leg. Other structures visualized
on the ultrasound were a blood vessel (BV), the distal
check ligament (DCL), the deep digital flexor tendon
(DDFT), and the superficial digital flexor tendon
(SDFT), ordered from dorsal to palmar (Figure 1a).
The horse had been treated for three weeks with con-
servative therapy. The oral application of anti-inflam-
Table 1. The isolated stem cells (SCs) from equine pe-
ripheral blood (ePB) were positive for hematopoietic SC
(HSC) markers CD34 and CD117, and for mesenchymal
SC (MSC) markers CD90 and CD105, and negative for
a differentiated blood cell marker, CD14 (Guest et al.,
2009; Martinello et al., 2009; Hoynowski et al., 2007). 
Marker HSCs MSCs SCs from ePB
CD14 - - -
CD34 + - +
CD90 - + +
CD105 - + +
CD117 + - +
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matory drugs (Fenylbutazon, 2g/day) for two weeks in
combination with cooling therapy four times a day for
three weeks with ice cold water for ten minutes on the
swollen leg did not improve the symptoms (Figure
1b). 
Stem cell therapy
Because this horse was clearly suffering, the owners
decided to try SC therapy. A blood sample was collec-
ted and, after isolation and enrichment of the auto-
logous SCs, 500 x103 cells in 5ml were injected locally
into the lesion with a sterile 2.5ml syringe and 20G
needle with multiple punctures. This was performed in
a sterile way and ultrasound guided in order to localize
the area of the lesion. After that, the owners were ad-
vised to immobilize the horse for ten days, followed by
walking exercises for three months and gradually in-
creasing the labor in the following three months to a
competitive level. 
Results
Five weeks after the SC injection the swelling had
disappeared and the horse showed no more signs of la-
meness. Moreover, the lesion was filled with tendon
tissue, although there was still some heterogenicity
noticeable at the edges of the lesion site (Figure 1c).
Nine weeks post-injection, there were no more signs of
the lesion on ultrasonography (Figure 1d). After the fol-
lowing nine weeks of walking exercises (i.e. 18 weeks
post-injection), the mare started trotting and cantering
gradually. At six months post-injection, , the horse re-
ached the original level of competition in show jum-
ping with no recurrence of the symptoms up to the pre-
sent (one year post-injection). 
Case report 2: bacterial ulcerative keratitis treated
with ePB-derived SCs
History
A 20-year-old Italian warmblood gelding was pre-
sented with a painful, inflamed eye with extensive tear
flow. A corneal ulcer was assumed, based on the results
of the fluorescein eye stain and on the clouded region
that was detected in the centro-ventral part of the eye.
The results of bacteriological examination had shown
that Pseudomonas aeruginosa was the main causing
agent of this pathological eye condition. The horse
had been treated for six months with different kinds of
antibiotics (gentamycin, tobramycin, tetracyclines,
chloramfenicol and colistine), non-steroid anti-in-
flammatory drugs (flunixin meglumine, sodium diclo-
fenac, and sodium flurbiprofen dehydrate) and other
farmaceutics (acetylcysteine, atropin sulfate, riboflavin,
xantopterin and d-α-tocoferol) with only a minimal
improvement of the symptoms. In addition, the local
application of miconazol was initiated, even though no
yeast or fungi had been isolated after a scraping sam-
ple. Because this ulcer appeared resistant against all the
possible conservative therapies, the owners chose for
surgical intervention. The ulcer was scraped and swab-
bed with iodide tincture (50% concentration). Never-
theless, the inflammation of the eye and the ulcer re-
mained present at the centroventral part of the eye in
spite of the different treatments for an exceedingly
long period (Figure 2a).
Stem cell therapy
Because there was so little improvement of the pa-
thological condition, the owners decided to try SC the-
Figure 2. Photos of a 20-year-old horse with a bacterial
ulcerative keratitis visualize the inflamed and ulcerated
right eye: (a) on the day of the SC therapy, (b) two weeks
post-therapy, and (c) three months post-therapy. The
general condition of the horse under identical manage-
ment circumstances is pictured: (d) on the day of stem
cell therapy and (e) three months after the day of SC
therapy. 
Figure 1. Transversal ultrasound images of the midregion
of the suspensory ligament (musculus interosseus medius,
MIM) of the right front leg of a 13-year-old Belgian
warmblood mare. Ultrasound images: (a) on the first day
of clinical signs, (b) on the day of SC therapy, (c) five
weeks post-therapy and (d) nine weeks post-therapy.
The lesions are encircled. BV: blood vessel; DCL: distal
check ligament; DDFT: deep digital flexor tendon;
SDFT: superficial digital flexor tendon.
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rapy as a last resort. A one-time injection both in the ju-
gular vein and in transverse facial artery (with a 27-
gauge butterfly catheter) was performed. The intrave-
nous injection with 125 x103 SCs in 5ml was performed
because of the poor general condition of the horse. The
intra-arterial injection, also with 125 x103 SCs in 5ml,
was performed in order to reach the internal structures
of the eye. In addition, a local application of ePB-de-
rived SCs was initiated with an eye drop formulation
of 500 x103 SCs in 5ml, three times a day for ten con-
secutive days. Resuspension of the sedimented cells
was performed by gently turning the bottle a couple of
times a day. After seven days, clouded areas were vi-
sible in the cell suspension, probably because of cell
death, and therefore the eye drop application was stop-
ped to avoid an inflammatory reaction to the necrotic
cells.
Results
Already two weeks later, positive effects were vi-
sible. The inflammation was starting to disappear and
the tear flow was decreasing. The size of the ulcer
was clearly reduced and remained stable (Figure 2b).
Three months after the SC treatment, the eye ulcer
was almost invisible and the inflammation had disap-
peared, along with the pain and irritation (Figure 2c).
Overall, the horse was in much better general condi-
tion, as is evident from a comparison of the photo in Fi-
gure 2d, which was taken before SC therapy, and the
photo in Figure 2e, which was taken three months af-
ter SC therapy. 
DISCUSSION
Stem cells (SCs) represent a very promising treat-
ment for certain types of degenerative or traumatic di-
seases because of their plasticity and differentiation ca-
pacities. Their use in equine veterinary medicine has
been intensively studied in recent years, and their re-
generative effect, mainly with tendon and ligament in-
juries, has been described in different independent in
vivo studies (Crovace et al., 2007; Smith et al., 2003;
Smith, 2008). 
In order to be classified as SCs, cells have to fulfill
several requirements that are clearly defined for human
SCs (International Society for Cellular Therapy
(ISCT), Dominici et al., 2006), although no such strict
definitions for veterinary stem cells have been esta-
blished to date. It is generally accepted that mesen-
chymal stem cells (MSCs), including those of equine
origin, must express several typical MSC markers, and
must also have the capacity to differentiate into adi-
pocytes, chondroblasts and osteoblasts (Dominici et al.,
2006). The characterization of equine MSCs is mostly
described by the presence of CD90 and CD105, and the
lack of CD14 and CD34 (Guest et al., 2009; Hoy-
nowski et al., 2007; Martinello et al., 2009). In the SC
population used in this study, the sorted cells were po-
sitive for 2 typical MSC markers, CD90 and CD105,
and they were also positive for two typical hemato-
poietic stem cells (HSC) markers, CD34 and CD117
(Table 1). This indicates the commitment of these SCs
towards the MSC lineage, since in the study by Marti-
nello et al. (2009) the MSC were also CD117 positive.
In order to state this with a higher level of certainty, dif-
ferentiation into different mesenchymal cell types
(chondroblasts, osteoblasts and adipocytes) of the me-
sodermal germ layer should be studied as described by
the ISCT for human SCs (Dominici et al., 2006). Up to
the present, however, no such experiments have been
done with the sorted ePB-derived SCs. The ‘stemness’
of these cells is based solely on the expression of cer-
tain SC markers. In a study by Koerner et al. (2006),
progenitor cells isolated from the ePB were clearly able
to differentiate into osteoblasts and adipocytes. Gio-
vannini et al. (2008) also described multilineage dif-
ferentiation potential, including differentiation into
chondroblasts of ePB progenitor cells. 
In human peripheral blood, approximately 28 cells
per 106 peripheral blood mononuclear cells (MNC)
are SCs (Bian et al., 2009). In horses, the number of
MNC (lymphocytes and monocytes) varies around
3.41 x106/ml blood (Cebulj-Kadunc et al., 2003). Ex-
trapolating the data from humans to horses, we estimate
that around 95 SCs/ml blood are present. In the present
study, 5ml of peripheral blood from the patients was
used, containing approximately 475 SCs (5 x 95).
These stem cells were then expanded for three days
with G-CSF, M-CSF, and IL 1, 3 and 6 (patent number
ThankStem: 07 820 134.0-1222), to obtain a sufficient
number (ranging from 500 to 750 x103 SCs) for thera-
peutic use.
For the regeneration of tendon tissue, bone marrow
is the most common source of equine MSCs, and it is
for this reason that such therapies are the best studied
until now (Smith et al., 2003; Smith, 2006; Smith,
2008) and, consequently, the differentiation of MSCs
from bone marrow into adipocytes, osteoblasts and
chondroblasts has been thoroughly studied as well
(Hegewald et al., 2004; Longobardi et al., 2001; Vidal
et al., 2006; Wilke et al., 2007). Since the goal of SC
therapy is to reach ‘restitutio ad integrum’ (restitution
of the original, functional state), these findings are
very promising and, all the more so, because they are
supported by several in vivo studies. In a study by
Hertel (2001), 84% of the horses with a suspensory li-
gament desmitis treated with bone marrow-derived
SCs returned to full work, in contrast to the conserva-
tive treatment, whereby only 15% of the horses reached
the same level as before. It must be noted, however,
that in this study no information was given on the fre-
quency of forelimb and hindlimb problems, which
have different prognoses. In another study, the benefi-
cial effects of SC therapy were evaluated in horses suf-
fering from superficial digital flexor tendinitis (Smith,
2008). This study found that 82% of the horses treated
with MSCs performed at their original level without re-
injury in the next year (Smith, 2008), whereas only
44% of the horses treated with conservative therapy did
so (Dyson, 2004). Here it should be mentioned that the
documentation from the control group spanned a lon-
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ger time frame post-treatment (two years) compared to
the study by Smith (2008).
In the first case study of the present report, SCs
from ePB were used to treat a horse suffering from a su-
spensory ligament desmitis. Although the cell injection
happened quite late in this case (after three weeks of
conservative therapy), the lesion soon showed very pro-
mising improvement on ultrasound, and six months la-
ter the horse was clinically normal, as she was show
jumping again and showed no signs of recurrence. Still,
it is important to point out that we do not know if this
horse would have shown the same improvement with a
conservative therapy for five more weeks. In order to
prove the effectiveness of SCs, we should have used a
standardized model with a similar induced lesion in a
significant number of horses. Also, a double blind setup
with half of the horses treated with SCs and the other
half with PBS and 5µM gentamycin (which is used as
a carrier to inject the stem cells) as a control group,
would have been an appropriate experimental setup.
On the other hand, there are the ethical questions that
arise from these kinds of clinical trials. Since we used
a spontaneously occurring tendon injury, a control group
with exactly the same lesion was not possible. More-
over, the horse went into competition again, which eli-
minated the option of histological examination.  
In the second case, SC therapy was applied to a
horse suffering from a painful bacterial ulcerative ke-
ratitis. For six months, different therapies were tried
without any success, for which reason, SCs were used
as a last resort. The use of SCs from ePB as a possible
treatment for corneal lesions or ulcers has not been des-
cribed in horses until now, although the use of eye SCs
and bone marrow-derived MSCs has been described
previously as a treatment for corneal lesions in a large
number of different mammal species such as mice,
rats, rabbits, horses and humans (Girolamo, 2009; Ji-
ang et al., 2010; Koizumi et al., 2009; Shimazaki et al.,
2002; Ueno et al., 2007). In the present case, the 20-
year-old horse with the corneal ulcer showed a positive
evolution after local, intravenous and intra-arterial SC
therapy, although further scientific research is needed
in order to understand their modus operandi and to be
able to propose a standardized protocol for using
equine SC therapy in the treatment of eye problems. In
human medicine, it has been pointed out that the in-
travenous application of adipose MSCs improved the
general condition and decreased the symptoms (pain,
coordination problems and loss of cognition) of three
multiple sclerosis (MS) patients (Riordan et al., 2009).
Since there were no control groups, the placebo effect
of the intravenous injections cannot be ruled out.
Therefore, the value of the intravenous application of
SCs in order to improve the general condition of this
horse is questionable. 
In conclusion, these reports describe long-lasting
pathologies that did not respond to conventional me-
dical treatment, for which reason SCs from ePB were
used as a novel therapy. Both horses showed significant
improvement after this treatment, a fact which indica-
tes the great potential of these SCs. Moreover, ePB is
a very interesting source of SCs because of the low in-
vasivity, ease of harvesting and low pain levels invol-
ved in the harvesting procedure (Kassis et al., 2006;
Zvaifler et al., 2000). Still, many questions remain
and more basic scientific research is certainly needed
to fully unravel the regenerative effects of SCs in ve-
terinary medicine in general, and in equine regenera-
tive therapy in particular. 
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